Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 28, 2018
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatinTomohiro Nishina, Mizutomo Azuma, Kazuhiro Nishikawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 9, 2016
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatinKazuhiro Nishikawa, Yasuhide Yamada, Kenji Ishido, et al.
Cancers|January 11, 2025
The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker AnalysesNaotoshi Sugimoto, Shingo Noura, Takeshi Kato, et al.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
International Journal of Clinical Oncology|January 7, 2016
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 aloneChikuma Hamada, Yasuhide Yamada, Mizutomo Azuma, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 30, 2015
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancerKohei Shitara, Kei Muro, Yasuhiro Shimada, et al.
Cancer Science|June 14, 2022
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancerKensei Yamaguchi, Keiko Minashi, Daisuke Sakai, et al.
Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.
Cancer Science|January 19, 2019
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancerTadamichi Denda, Daisuke Sakai, Tetsuya Hamaguchi, et al.
British Journal of Cancer|March 4, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trialYasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.
Pageof 19